Aparicio Paula, López-Royo Tresa, Navarrete-Villanueva David, Gómez Cabello Alba María, González-Gross Marcela, Ara Ignacio, Vicente-Rodríguez Germán, Osta Rosario, Manzano Raquel
LAGENBIO, Faculty of Veterinary, University of Zaragoza, Miguel Servet 177, 50013, Zaragoza, Spain.
Centre for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, 28029, Madrid, Spain.
Noncoding RNA Res. 2025 Jun 23;14:166-176. doi: 10.1016/j.ncrna.2025.06.003. eCollection 2025 Oct.
Sarcopenia, the loss of muscle mass and function generally associated to age, leads to increased dependence and mortality in older adults. Despite its clinical significance, unclear molecular mechanisms hinder the development of universal diagnostic and therapeutic monitoring methods. Recent research suggests long non-coding RNAs (lncRNAs) as potential biomarkers for muscle damage and sarcopenia. This study investigates the role of six specific lncRNAs as biomarkers for diagnosing and monitoring sarcopenia following physical training. For this purpose, an initial cohort of participants was divided into two experiments: Trial 1, a cross-sectional study comprising 54 sarcopenic patients and 29 robust controls, both including men and women; Trial 2, a non-randomized controlled trial, where the same sarcopenic patients from Trial 1 were divided in two groups: a Control Group (CG, n = 15); and a Trained Group (TG, n = 22). RNA was extracted from serum samples for all the participants, and the expression of 6 lncRNA (PVT1, HOTAIR, MALAT1, NEAT1, GAS5, H19), selected from the literature, was quantified by RT-PCR and compared between the different groups. Statistical evaluation uncovered four lncRNAs with significantly distinct expression in Trial 1: PVT1 (LOG2FC = 1.194), GAS5 (LOG2FC = 0.8224), NEAT1 (LOG2FC = 1.497) and H19 (LOG2FC = -0.9958) and three lncRNA significantly different between TG and CG in Trial 2 (PVT1 (LOG2FC = -1.796), MALAT1 (LOG2FC = 2.834) and H19 (LOG2FC = 1.355). Among them, NEAT 1 stands aout as promissing diagnostic marker ans PVT1 and H19 may serve as both diagnosis and treatment monitoring, altough further validation in larger cohorts is needed to confirm these results.
肌肉减少症是一种通常与年龄相关的肌肉质量和功能丧失，会导致老年人的依赖性增加和死亡率上升。尽管其具有临床意义，但尚不明确的分子机制阻碍了通用诊断和治疗监测方法的发展。最近的研究表明，长链非编码RNA（lncRNA）可能是肌肉损伤和肌肉减少症的生物标志物。本研究调查了六种特定lncRNA作为体育锻炼后诊断和监测肌肉减少症生物标志物的作用。为此，最初的一组参与者被分为两个实验：实验1，一项横断面研究，包括54名肌肉减少症患者和29名健康对照者，两者均包括男性和女性；实验2，一项非随机对照试验，将实验1中相同的肌肉减少症患者分为两组：对照组（CG，n = 15）；和训练组（TG，n = 22）。从所有参与者的血清样本中提取RNA，并通过RT-PCR对从文献中选择的6种lncRNA（PVT1、HOTAIR、MALAT1、NEAT1、GAS5、H19）的表达进行定量，并在不同组之间进行比较。统计评估发现，在实验1中有四种lncRNA具有明显不同的表达：PVT1（LOG2FC = 1.194）、GAS5（LOG2FC = 0.8224）、NEAT1（LOG2FC = 1.497）和H19（LOG2FC = -0.9958），在实验2中TG和CG之间有三种lncRNA有显著差异（PVT1（LOG2FC = -1.796）、MALAT1（LOG2FC = 2.834）和H19（LOG2FC = 1.355）。其中，NEAT1作为一种有前景的诊断标志物脱颖而出，PVT1和H19可能同时用于诊断和治疗监测，不过需要在更大的队列中进行进一步验证以证实这些结果。
